Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

[1]  A. Blackford,et al.  Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer , 2021, Frontiers in Genetics.

[2]  A. Benson,et al.  Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11. , 2021 .

[3]  C. Adithan,et al.  Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer , 2021, PloS one.

[4]  C. Loprinzi,et al.  Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms. , 2020, JCO oncology practice.

[5]  Jason C. Young,et al.  The Evolution of Duplicated Genes of the Cpi-17/Phi-1 (ppp1r14) Family of Protein Phosphatase 1 Inhibitors in Teleosts , 2020, International journal of molecular sciences.

[6]  B. Yaremko,et al.  Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients , 2020, Breast Cancer Research and Treatment.

[7]  A. Leroux,et al.  Identification of Specific Tumor Markers in Vulvar Carcinoma Through Extensive Human Papillomavirus DNA Characterization Using Next Generation Sequencing Method. , 2020, Journal of lower genital tract disease.

[8]  A. Boyle,et al.  Predicting functional variants in enhancer and promoter elements using RegulomeDB , 2019, Human mutation.

[9]  Arthur S Slutsky,et al.  The plasma peptides of ovarian cancer , 2018, Clinical Proteomics.

[10]  J. Perea,et al.  A novel nonsense variant in SUPT20H gene associated with Rheumatoid Arthritis identified by Whole Exome Sequencing of multiplex families , 2018, bioRxiv.

[11]  G. Rosner,et al.  A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial , 2018, Breast Cancer Research and Treatment.

[12]  J. Rae,et al.  Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer , 2017, Physiological genomics.

[13]  Ana Cernea,et al.  Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm , 2017, Cancer medicine.

[14]  C. Moinpour,et al.  Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Gary D Bader,et al.  Association analysis identifies 65 new breast cancer risk loci , 2017, Nature.

[16]  P. Neven,et al.  Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation , 2017, Clinical breast cancer.

[17]  M. Kris,et al.  Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment , 2017, JAMA.

[18]  D. Kroetz,et al.  Genetic advances uncover mechanisms of chemotherapy‐induced peripheral neuropathy , 2017, Clinical pharmacology and therapeutics.

[19]  J. Rae,et al.  Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients. , 2017, Pharmacogenomics.

[20]  G. Gervasini,et al.  Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients , 2017, British journal of clinical pharmacology.

[21]  D. Beckwée,et al.  Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis , 2017, Supportive Care in Cancer.

[22]  Matthias W. Beckmann,et al.  Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation , 2016, American journal of human genetics.

[23]  Alan M. Kwong,et al.  Next-generation genotype imputation service and methods , 2016, Nature Genetics.

[24]  Tom R. Gaunt,et al.  Systematic identification of genetic influences on methylation across the human life course , 2016, Genome Biology.

[25]  Todd C. Skaar,et al.  Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer , 2016, The oncologist.

[26]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[27]  Lei Liu,et al.  RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients , 2015, PloS one.

[28]  L. Moscetti,et al.  Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment? , 2015, Tumori.

[29]  P. Neven,et al.  CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial , 2015, Breast Cancer Research and Treatment.

[30]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[31]  H. Putter,et al.  Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial , 2014, Breast Cancer Research and Treatment.

[32]  D. Wallwiener,et al.  COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Wei Xiao,et al.  The p38-interacting Protein (p38IP) Regulates G2/M Progression by Promoting α-Tubulin Acetylation via Inhibiting Ubiquitination-induced Degradation of the Acetyltransferase GCN5* , 2013, The Journal of Biological Chemistry.

[34]  J. Farrar,et al.  Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors , 2013, BMC Cancer.

[35]  Qingyuan Zhang,et al.  Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer , 2013, PloS one.

[36]  A. Díez-Pérez,et al.  Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study , 2013, Breast Cancer Research and Treatment.

[37]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[38]  Steffi Oesterreich,et al.  Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer , 2013, Breast Cancer Research and Treatment.

[39]  Jane E. Carpenter,et al.  A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. , 2012, Human molecular genetics.

[40]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[41]  Lang Li,et al.  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Lang Li,et al.  Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age , 2011, Clinical pharmacology and therapeutics.

[43]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[44]  Yusuke Nakamura,et al.  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Banerjee,et al.  A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography , 2010, Cancer.

[46]  G. Uhl,et al.  Effect of KEPI (Ppp1r14c) deletion on morphine analgesia and tolerance in mice of different genetic backgrounds: when a knockout is near a relevant quantitative trait locus , 2010, Neuroscience.

[47]  Jemma L. Webber,et al.  Coordinated regulation of autophagy by p38α MAPK through mAtg9 and p38IP , 2010, The EMBO journal.

[48]  J. Farrar,et al.  Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors , 2009, Cancer.

[49]  J. Cuzick,et al.  Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. , 2008, The Lancet. Oncology.

[50]  H. Greenlee,et al.  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Cummings,et al.  Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. , 2005, Arthritis and rheumatism.

[52]  E. Perez,et al.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.

[53]  P. Schultz,et al.  Cancer Survivors , 2002, AAOHN journal : official journal of the American Association of Occupational Health Nurses.

[54]  G. Uhl,et al.  KEPI, a PKC-dependent Protein Phosphatase 1 Inhibitor Regulated by Morphine* , 2002, The Journal of Biological Chemistry.

[55]  Krishna R. Kalari,et al.  Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor‐Induced Arthralgias: An Analysis of CCTG MA.27 , 2018, Clinical breast cancer.